Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 92

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part II, Item 3
Chunk 92
---
 Listing Rule 5810(c)(3)(A), we were provided 180 calendar days, or util August 6, 2025, to
regain compliance with the rule.

In
addition, on May 27, 2025 we received written notice from the Staff stating that we were not in compliance with Nasdaq Listing Rule 5550(b)(1)
(the “Continued Listing Equity Requirement”) because our stockholders’ equity of $1,439,404 as of March 31, 2025, as
reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, was below the minimum requirement of
$2,500,000. Pursuant to Nasdaq’s Listing Rules, we had 45 calendar days to submit a plan to regain compliance (a “Compliance
Plan”) with the Continued Listing Equity Requirement. On July 14, 2025, the Company submitted its plan to regain compliance with
the Continued Listing Equity Requirement.

On
August 7, 2025, we received written notice from the Listing Qualifications Staff of Nasdaq that we had not regained compliance with the
Minimum Bid Price Requirement by August 6, 2025 and were not eligible for a second 180-day compliance period as we did not comply with
the minimum stockholders’ equity requirement for initial listing on the Nasdaq Capital Market. As a result, unless we requested
an appeal to a hearings panel (the “Panel”) by August 14, 2025, our securities would be scheduled for delisting from The
Nasdaq Capital Market and would be suspended at the opening of business on August 18, 2025.

We
submitted an appeal to Nasdaq on August 14, 2025, which stayed the delisting and suspension of the Company’s securities pending
the decision of the Panel. On August 14, 2025, we received written notice from Nasdaq that our hearing has been scheduled for September
11, 2025. At the hearing, the Company presented its views and its plans to regain compliance with the Minimum Bid Price Requirement and
the Continued Listing Equity Requirement to the Panel. On September 18, 2025, Nasdaq granted us an extension until October 2, 2025 to
demonstrate compliance with the Minimum Bid Price Requirement and Continued Listing Equity Requirement. On October 14, 2025, the Company
received a letter from Nasdaq